Frequency and prognosis of associated malignancies in 504 patients with lymphomatoid papulosis by Melchers, R.C. (R. C.) et al.
ORIGINAL ARTICLE
Frequency and prognosis of associated malignancies in 504
patients with lymphomatoid papulosis
R.C. Melchers,1,* R. Willemze,1 M.W. Bekkenk,2 E.R.M. de Haas,3 B. Horvath,4 M.M. van Rossum,5
C.J.G. Sanders,6 J.C.J.M. Veraart,7 H. Putter,8 P.M. Jansen,9 M.H. Vermeer,1 K.D. Quint1
1Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands
2Department of Dermatology, Academic Medical Center, Vrije University Medical Center, Amsterdam, The Netherlands
3Department of Dermatology, Erasmus Medical Center, Rotterdam, The Netherlands
4Department of Dermatology, University Medical Center of Groningen, Groningen, The Netherlands
5Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands
6Department of Dermatology, University Medical Center Utrecht, Utrecht, The Netherlands
7Department of Dermatology, Maastricht University Medical Center, Maastricht, The Netherlands
8Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands
9Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
*Correspondence: R.C. Melchers. E-mail: r.c.melchers@lumc.nl
Linked article: F. Rongioletti. J Eur Acad Dermatol Venereol 2020; 34: 216–217. https://doi.org/10.1111/jdv.16157.
Abstract
Background Lymphomatoid papulosis (LyP) can be associated with other haematological malignancies (HM), but
reported percentages vary from 20% to over 50%.
Objective To evaluate the frequency and prognostic signiﬁcance of associated HM and non-HM in LyP patients.
Methods In this multicentre cohort study, the complete Dutch LyP population was included from the Dutch Cutaneous
Lymphoma Registry between 1985 and 2018. Clinical and histopathological information was retrieved from every individ-
ual patient.
Results After a median follow-up of 120 months (range, 6–585), an associated HM was observed in 78/504 (15.5%)
patients. Most common associated HM were mycosis fungoides (MF; n = 31) and anaplastic large-cell lymphoma (ALCL;
n = 29), while 19 patients had another HM of B-cell (n = 14) or myeloid origin (n = 5). Even after a 25-year follow-up per-
iod, percentages of associated HM did not exceed 20%. Thirty-nine of 465 patients (8.4%) without a prior or concurrent
associated HM developed an associated HM during follow-up, after a median of 68 months (range of 3–286 months).
Nine of 78 patients died of associated HM, including 6/22 patients developing extracutaneous ALCL, while all patients
with associated MF or skin-limited ALCL had an excellent prognosis. Compared with the general population, LyP
patients showed an increased risk (relative risk, 2.8; 95% conﬁdence intervals, 2.4–3.3) for non-HM, in particular cuta-
neous squamous cell carcinoma, melanoma and intestinal/lung/bladder cancer.
Conclusions An associated HM was reported in 15.5% of the LyP patients, particularly MF and ALCL. Although the fre-
quency of associated HM is lower than suggested and the prognosis of most patients with associated HM is excellent, a
small subgroup will develop aggressive disease, in particular extracutaneous ALCL. Furthermore, LyP patients have a higher
risk of developing othermalignancies. Clinicians should be aware of these risks, and LyP patients require closemonitoring.
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Introduction
Lymphomatoid papulosis (LyP) is a chronic, recurrent skin dis-
ease, clinically characterized by the presence of self-healing
papular, papulonecrotic and/or nodular skin lesions with histo-
logic features of a CD30+ cutaneous T-cell lymphoma (CTCL).
LyP has overlapping clinical and histopathological features with
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primary cutaneous anaplastic large-cell lymphoma (C-ALCL),
and both conditions form a spectrum of primary cutaneous
CD30+ lymphoproliferative diseases.1–4 LyP has an excellent
prognosis with a 5-year disease-specific survival near 100%.1,2,4
However, in a subset of patients, LyP may be associated with
another type of haematological malignancy (HM), most com-
monly mycosis fungoides (MF), ALCL or Hodgkin lymphoma,
and these patients may have an unfavourable prognosis.5,6 The
incidence of these LyP-associated HM reported in the literature
shows wide variation, while most studies described associated
HM in approximately 15–20% of LyP patients, and more recent
studies report percentages up to 50%.5–17 These differences may
be due to referral bias, differences in duration of follow-up or
differences in criteria used for the diagnosis of an associated
HM. However, more precise information about the risk to
develop an associated HM or non-HM is important, since it
may have consequences for the management and treatment of
patients with LyP.18 In the present study, we therefore evaluated
the frequency and prognostic significance of associated HM as
well as non-HM in the largest, most comprehensive and unbi-
ased cohort to date of 504 LyP patients with long-term follow-
up included in the Dutch registry of cutaneous lymphomas.
Methods
Patient selection
Between October 1985 and February 2018, 515 patients with LyP
were included in the Dutch Registry of Cutaneous Lymphomas
(DRCL). In all cases, the diagnosis was based on the clinico-
pathologic criteria of the WHO-EORTC classification and con-
firmed by an expert panel of dermatologists and pathologists of
the Dutch Cutaneous Lymphoma Group.4 Yearly collected fol-
low-up data were retrieved from the DRCL. Missing information
was collected from medical records and referring clinicians.
In addition, the presence of associated HM and non-HM was
investigated by retrieving the results of all histologic examina-
tions of every patient using the nationwide network and registry
of histo- and cytopathology in the Netherlands (PALGA Foun-
dation).19 Living patients with a follow-up duration <12 months
and/or incomplete follow-up data were excluded (n = 11). The
final study group consisted of 504 LyP patients, including 118
patients evaluated in 2000 by Bekkenk et al.5 This multicentre
study was evaluated by the institutional review board and pro-
vided with a waiver of consent.
Deﬁnition of associated haematological malignancies
In all cases, the diagnosis of an associated HM was confirmed by
review of the histologic sections. Many LyP patients have
eczematous skin lesions with variable clinical resemblance to
early-stage MF, but do not meet the histopathologic criteria of
MF. Therefore, a diagnosis of associated MF was only made if
confirmed histologically using well-established criteria.4,20
Patients with LyP may be preceded by or develop lesions with
clinicopathologic features consistent with an ALCL in skin and/
or extracutaneous sites. It is, however, arbitrary if and when
tumours developing in patients with LyP should be considered
as C-ALCL or still as LyP. In the present study, the occurrence of
tumours was recorded in every patient. Diagnosis of C-ALCL
was only made in case of a skin lesion that did not disappear
spontaneously and was treated with radiotherapy or excision.
Tumours with a diameter of 1–4 cm coexisting with papular
lesions and disappearing spontaneously, recorded in three
patients, were not considered to represent progression to ALCL.
Each associated lymphoma was counted only once; relapsed
lymphoma or disease progression was not counted as a new
malignancy.
Statistical analysis
All statistical analyses were performed using SPSS version 23 sta-
tistical software (IBM Corp, Armonk, NY). All analyses of time
to lymphoma and incidence rates were based on patients free of
associated malignancies at time to diagnosis. The Kaplan–Meier
technique was used to compute time to associated malignancy,
measured from diagnosis of LyP. The incidence rates, relative
risk (RR) and 95% confidence intervals (CIs) of associated
malignancies in LyP cases in our cohort were calculated and
were compared with 1-year incidence rates, corrected for age
and gender, of (non-)HM in persons from the Dutch cancer reg-
istration (IKNL/NKR), which includes the complete Dutch pop-
ulation and is based on the guidelines of the World Health
Organization.21 A P-value of <0.05 was considered significant.
Results
The final study group included 286 males and 218 females (male-
to-female ratio: 1.3 : 1). Median age at time of diagnosis was
47 years (range, 2–92 years). The study group contained 52
patients younger than 20 years of age at the time of diagnosis
(median, 11 years; range: 2–19 years). After a median follow-up
of 120 months (range, 6–585 months), an associated HM was
found in 78 of 504 patients (15.5%; Table 1). Thirty-nine patients
developed an associated HM before (n = 25) or concurrent with
(n = 14) diagnosis of LyP and 39 patients 3–286 months (me-
dian 68 months) after the diagnosis of LyP. One patient devel-
oped two different associated lymphomas (MF and C-ALCL).
Three groups of associated HM were distinguished: patients
with MF (n = 31), patients with ALCL in skin and/or extracuta-
neous sites (n = 29) and a miscellaneous group of malignancies
of B-cell and myeloid origin (n = 19).
Since previous studies suggested that increased percentages of
associated HM are due to prolonged follow-up periods, we per-
formed a subgroup analysis of patients included in the database
before 2005. After a median of 217 months, 42/227 (18.5%) of
the patients developed an associated HM, which is not different
from the percentage observed in the whole study group. This is
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further supported by a Kaplan–Meier curve illustrating the
development of an associated HM plotted against time, which
seems to stabilize around 20% (Fig. 1).
Compared with the general population, LyP patients without
prior or concurrent associated HM at time of diagnosis have a
significantly increased risk of developing an associated HM (RR,
11.9; 95% CI, 8.3–15.5). When evaluating the risk of developing
MF or C-ALCL apart, the RR was increased dramatically (RR,
460.7; 95% CI, 298.5–622.8). An increased, but not significant,
risk was found when evaluating the risk of developing a B-cell
lymphoma separately (RR, 2.95; 95% CI, 0.6–5.3).
LyP associated with mycosis fungoides
This subgroup of 31 patients contained 21 males and 10 females.
The median age at diagnosis of LyP was 56 years (range, 30–
87 years) and 54 years (range, 32–88 years) for MF. MF was
diagnosed in seven patients before, in 13 patients concurrent
with, and in 11 patients after the diagnosis of LyP (Table 2).
Twenty-two patients had MF stage IA and nine patients MF
stage IB. None of the 31 patients with the combination of LyP
and MF progressed to tumour stage MF or developed
extracutaneous localizations. Treatment of MF was expectative
(n = 18), or with PUVA/UVB (n = 12), and only one patient
received radiotherapy for extensive plaques. After a median fol-
low-up period of 67 months after the diagnosis of MF (range,
10–409 months), six patients were alive without MF, 17 patients
were alive with MF, and 8 patients died of unrelated disease.
LyP with associated (cutaneous) ALCL
This subgroup contained 29 patients including 19 males and 10
females (male-to-female ratio 1.9 : 1). The median age at diag-
nosis of LyP was 47 years (range, 20–77 years) and 49 years
(range, 30–83 years) for ALCL. Diagnosis of ALCL was made in
10 patients before and in 19 patients after LyP (Table 3). Eight
of 29 patients (nos. 1–8) presented with only a persistent skin
tumour before (n = 3) or after (n = 5) the diagnosis of LyP had
been made. Treatment with local radiotherapy in six cases, exci-
sion in one case and CHOP courses in one case resulted in com-
plete remission in all of them. After a median follow-up of
175 months (range, 82–365 months), only one of these patients
developed systemic disease and died of ALCL (no. 8).
Altogether, 22 patients developed ALCL at extracutaneous
sites with or without persistent skin lesions. Systemic localiza-
tions preceded LyP in seven cases and developed after the diag-
nosis of LyP in the other 15 patients. Notably, none of the seven
LyP patients with preceding systemic localizations died of lym-
phoma. Sixteen patients were treated with CHOP or CHOP-like
courses, in two of them followed by an allogeneic stem cell trans-
plantation, two patients were treated with local radiotherapy,
while two patients received no treatment and in one patient both
skin and nodal lesions disappeared spontaneously. Six patients,
who developed ALCL 4–140 months (median 36 months) after
the diagnosis of LyP had been made, died 4–94 months (me-
dian, 6.5 months) after the diagnosis.
Interestingly, five patients (cases 10, 11, 14, 16 and 17) who
developed a single persistent tumour and extracutaneous
involvement restricted to one draining lymph node had an excel-
lent prognosis. Treatment with CHOP courses in four patients
and spontaneous regression of both skin and nodal lesions in
one patient resulted in sustained complete remissions with no
new ALCL lesions after a follow-up period of 9.5–25 years.
Other haematological malignancies
In total, 19 other associated HM were reported, mainly of B-cell
(n = 14) or myeloid origin (n = 5; Table 4). Four cases were
initially diagnosed as Hodgkin lymphoma. However, after
reviewing the histologic sections two cases were reclassified as
ALCL, because of expression of T-cell and/or cytotoxic markers,
without expression of B-cell markers (PAX-5, CD79a, CD20).
Nine patients developed a lymphoma/leukaemia before or con-
current with diagnosis of LyP, and 10 patients after. Three
patients died of associated disease, one of Hodgkin lymphoma
and two of myeloid leukaemias.
Table 1 Associated haematological malignancies in lymphoma-
toid papulosis (LyP)
Before Concurrent After Total D+‡
Mycosis fungoides 7 13 11 31 0
Anaplastic large-cell
lymphoma
10 0 19 29 6
Skin 3 0 5 8 1
Extracutaneous
 skin
7 0 14 21 5
Other† 8 1 10 19 3
†Includes Hodgkin lymphoma, B-cell lymphoma/leukaemia and myeloid leu-
kaemia. ‡Died of (associated) lymphoma or leukaemia.
Figure 1 Time to associated haematological malignancy, mea-
sured from diagnosis of lymphomatoid papulosis.
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology
JEADV 2020, 34, 260–266
262 Melchers et al.
Non-haematological malignancies and atopic dermatitis
After retrieving the results of all histologic examinations of 456
patients (PALGA Foundation), a total number of 195 non-HM
were observed in 146 (32%) patients (Table 5). Comparative
statistical analysis was performed, in which basal cell carcinomas
(n = 52) and Bowen’s (n = 10) disease were excluded as associ-
ated non-HM, since these are not included in the national cancer
registry. Compared with the general population, LyP patients
have a significantly increased risk of developing a non-HM (RR,
2.8; 95% CI, 2.4–3.3). Subsequent risk evaluation of separate
types of malignancies resulted in a significantly increased risk of
developing cutaneous squamous cell carcinoma (RR, 4.3; CI,
2.5–6.1), melanoma (RR, 4.2; CI, 1.8–6.6), lung cancer (RR, 3.7;
CI, 2.1–5.2), intestinal cancer (RR, 2.4; CI, 1.2–3.7) and bladder
cancer (RR, 8.1; CI, 3.1–13.1; Table 5). Also, an atopic dermati-
tis prevalence of 83 of 288 (29%) evaluable patients was found.
Discussion
In the present comprehensive study of 504 patients with LyP, an
associated HM was found in 78 patients (15.5%). MF (31 cases;
6.2%) and ALCL (29 cases; 5.8%) were the most common asso-
ciated HM, while there were 19 patients (3.8%) with another
type of HM including Hodgkin lymphoma, different B-cell neo-
plasms and myeloid leukaemias. Whereas detection of shared
clonality in skin lesions of LyP and associated MF as well as in
lesions of LyP and associated ALCL suggest a biologic
Table 2 Individual patient characteristics of LyP patients with an associated MF
No Sex Age Time interval
(months)†
Stage‡ Treatment MF Current status (follow-up in
months)
MF LyP
1. M 58 A (52) IA PUVA Do (232) Do (284)
2. F 71 B (3) IB PUVA A+ (326) A+ (323)
3. F 56 B (72) IB PUVA Do (409) Do (337)
4. F 59 A (274) IA Expectative Do (57) Do (331)
5. M 44 C IA Expectative Do (177) Do (177)
6. F 87 C IB PUVA Do (23) Do (23)
7. M 80 A (97) IB UVB Do (13) Do (110)
8. M 58 B (148) IB RT Ao (225) A+ (77)
9. M 64 B (91) IB UVB Do (163) Do (72)
10. M 66 A (24) IA UVB Ao (178) Ao (202)
11. F 55 B (208) IA Expectative Ao (236) A+ (28)
12. M 51 C IA PUVA A+ (42) A+ (42)
13. M 70 B (143) IB PUVA A+ (261) A+ (118)
14. M 56 A (144) IB UVB A+ (92) A+ (236)
15. M 62 A (50) IA Expectative A+ (107) Ao (157)
16. F 64 C IA Expectative Do (87) Do (87)
17. M 42 A (108) IA Expectative Ao (15) A+ (123)
18. M 37 C IA Expectative A+ (124) A+ (124)
19. M 43 C IA UVB A+ (129) Ao (129)
20. M 54 A (71) IA Expectative A+ (31) A+ (102)
21. M 51 A (36) IA Expectative A+ (49) A+ (85)
22. M 69 C IA Expectative A+ (76) A+ (76)
23. M 48 B (18) IA Expectative Ao (67) Ao (49)
24. F 30 A (34) IA Expectative A+ (24) A+ (58)
25. M 35 A (48) IA Expectative A+ (10) A+ (58)
26. F 49 C IB UVB A+ (41) A+ (41)
27. M 50 C IA Expectative A+ (41) Ao (41)
28. M 36 C IA Expectative A+ (24) A+ (24)
29. F 77 C IA Expectative A+ (12) A+ (12)
30. M 65 C IA Expectative Ao (16) A+ (16)
31. M 53 C IA Expectative A+ (14) A+ (14)
†Associated lymphoma before (B) concomitant with (C) or after (A) diagnosis of lymphomatoid papulosis. ‡IA, patches/plaques <10% body surface. IB,
patches/plaques >10% body surface.
A+, alive with disease; Ao, alive no evidence of disease; Do, died of unrelated disease; LyP, lymphomatoid papulosis; MF, mycosis fungoides; RT, radiotherapy.
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relationship between LyP and MF/ALCL, the relationship
between LyP and these other types of HM is probably
coincidental.
LyP patients with an associated HM do not necessarily have a
poor outcome. The prognosis of patients with the combination
of LyP and MF is usually excellent, and MF-related deaths have
rarely been reported.12 In the present study, all 31 patients with
associated MF had early-stage disease and none of them pro-
gressed to tumour stage disease or developed extracutaneous dis-
ease. In the group of patients with associated ALCL, patients
with skin-limited tumours generally had a favourable prognosis.
Only one of eight patients developed systemic disease and died
of ALCL. LyP patients developing nodal or visceral localizations
are more at risk. In the present study, six of 22 patients develop-
ing extracutaneous disease died of associated ALCL. Interest-
ingly, five patients with a single persistent tumour and
involvement of only one draining lymph node had an excellent
prognosis. Altogether, 9 of 78 patients with an associated HM
died of lymphoma or leukaemia, including six of ALCL, one of
Hodgkin lymphoma and two of myeloid leukaemia.
Several risk factors for an associated HM have been suggested,
such as age, male sex, histologic subtype of LyP and the presence
Table 3 Individual patient characteristics of LyP patients with an associated CD30+ anaplastic large-cell lymphoma
Sex/Age (y) Time interval
(months)†
Localization Treatment
(response)
Current status (follow-up in
months)
Skin EC Lymphoma LyP
1. F/71 A (48) +  RT (CR) Ao (275) A+ (323)
2. M/57 B (16) +  CHOP (CR) Do (365) Do (349)
3. F/45 A (3) +  RT (CR) Do (277) Do (280)
4. M/20 A (182) +  RT (CR) Ao (147) A+ (329)
5. M/52 A (118) +  RT (CR) Ao (114) A+ (232)
6. M/62 A (75) +  RT (CR) Do (82) Do (157)
7. M/31 B (7) +  RT (CR) Ao (203) Ao (196)
8. M/59 B (47) +  Excision (CR) D+ (94) D+ (47)
A (25)  + CHOP (PR)
9. M/27 A (51) + + CHOP (CR) Do (348) Do (399)
10. F/33 B (33) + +‡ CHOP (CR) Ao (309) Ao (276)
11. M/31 A (68) + +‡ CHOP (CR) Ao (255) A+ (323)
12. F/55 B (136) + + CHOP (CR) Ao (241) A+ (105)
13. M/71 A (47) + + Died before treatment D+ (4) D+ (51)
14. M/55 B (5) + +‡ CHOP (CR) Ao (136) A+ (131)
15. M/42 A (70) + + CHOP (PR) Ao (64) Ao (134)
A (81)  + BV + alloSCT (CR)
16. F/42 B (24) + +‡ RT + CHOP (CR) Ao (114) A+ (90)
17. F/52 A (60) + +‡ Spontaneous regression Ao (300) Ao (360)
18. F/45 B (24)  + RT (CR) Do (113) Do (89)
19. M/43 A (78)  + CHOP (CR) Ao (177) Ao (255)
20. M/37 A (230)  + CHOP (CR) Ao (71) A+ (301)
21. M/49 B (157, 49)  + RT (CR), MOPP (CR) Ao (395) A+ (238)
22. M/46 A (140)  + CHOP (NR) D+ (7) D+ (147)
23. F/47 A (10)  + Refused treatment D+ (4) D+ (14)
24. M/43 A (25)  + Alemtuzumab + CHOP
+ alloSCT (CR)
Ao (122) Ao (147)
25. M/77 A (78)  + CHOP (PD) D+ (6) D+ (84)
26. M/43 A (4)  + CHOP (NR) D+ (7) D+ (11)
27. M/65 A (12)  + CHOP + RT (CR) Ao (94) Ao (106)
28. F/64 B (16)  + CHOP (CR) Ao (34) A+ (18)
29. F/71 A (25)  + RT (CR) Ao (16) Ao (41)
†Associated lymphoma before (B) or after (A) the diagnosis of lymphomatoid papulosis. ‡Patients with a solitary tumour with extracutaneous disease
restricted to one regional draining lymph node.
A+, alive with disease; AlloSCT, allogeneic stem cell transplantation; Ao, alive no evidence of disease; CHOP, cyclophosphamide, doxorubicin, vincristine and
prednisone; CR, complete remission (100%); D+, died of lymphoma; Do, died of unrelated disease; EC, extracutaneous localizations of CD30+ lymphoprolifera-
tive disease (CTCL); LyP, lymphomatoid papulosis; NR, no remission (0–50%); PD, progressive disease; PR, partial remission (>50%); RT, radiotherapy.
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of a T-cell clone.7–12,22 However, the results of these studies are
conflicting, and risk factors for those rare patients developing
systemic and potentially fatal disease are unknown.
The result of the present study shows an associated HM in
15.5% of LyP patients, but deviates significantly from the
results of recent studies, which reported percentages up to
50%.5,7–10,12,16 There are several explanations for the discrepancy
in the frequency of associated HM in different studies, and refer-
ral bias has been suggested as the major cause.12 All dermatolo-
gists working in peripheral institutes in the Netherlands refer
patients with a diagnosis of (suspected) cutaneous lymphoma,
including patients with LyP, to dermatologists in university hos-
pitals. Since 1985, all patients with a CTCL, seen in one of the
eight Dutch university hospitals, are discussed periodically by a
multidisciplinary panel of dermatologists and pathologists and
all cases are included in the DRCL. In this way, it is highly unli-
kely that referral bias plays a significant part in our study.
A second explanation might be selection bias resulting from
differences in the criteria used for diagnosis of these associated
HM. Notably, in none of the previous studies definitions for
associated HM were provided. In the present study, diagnosis of
MF was only made if confirmed by histologic examination. This
is important since a considerable proportion of LyP patients
may show, in addition to the typical LyP lesions, skin lesions
clinically suspect of early-stage MF. The association between LyP
or other cutaneous lymphomas and atopy/atopic dermatitis has
been described before and was found in 83 of 288 (29%) evalu-
able patients in the present study.23–25 This might even be an
underestimation, since the presence of atopic dermatitis was not
recorded adequately in the past. It is more difficult how C-ALCL
should be defined in this setting. Diagnosis of C-ALCL was made
in case of persistent tumours, treated with radiotherapy or exci-
sion, while tumours showing complete spontaneous resolution
were not considered to represent progression to ALCL.
Our results argue against the suggestion that differences in the
percentages of associated HM could be explained by differences
in the duration of follow-up between studies.8 Evaluation of a
subgroup of 227 LyP patients diagnosed between 1985 and 2004
with a median follow-up of 217 months showed an associated
HM in 42 patients (18.5%), which is similar to the whole cohort.
Because patients are monitored yearly, and associated HM were
also identified by evaluating pathology reports using the national
histopathology (PALGA) database, it is unlikely that associated
HM were missed.
The present study also revealed a significant higher incidence
of associated non-HM compared with the general Dutch popu-
lation (RR, 2.8), in particular for cutaneous squamous cell carci-
noma, malignant melanoma and a number of internal cancers.
An increased risk for cutaneous squamous cell carcinoma and
malignant melanoma might be explained by common external
factors, such as UV exposure and frequent physical examinations
of the skin, or shared (epi)genetic alterations.18,26,27 Thus, clini-
cians should be aware of this increased risk, during skin exami-
nation of an LyP patient. An explanation for the increased risk
for internal non-HM is currently lacking.
Table 4 Frequencies of associated miscellaneous lymphomas/
leukaemias
Before Concurrent After Total
Hodgkin lymphoma 1 0 1 2
B-cell lymphoma/leukaemia 6 0 6 12
• MALT lymphoma 0 0 1 1
• Multiple myeloma 1 0 1 2
• Systemic follicular
lymphoma
3 0 1 4
• Diffuse large
B-cell lymphoma
0 0 2 2
• Burkitt lymphoma 1 0 0 1
• Methotrexate-
associated B-cell LPD
0 0 1 1
• B-cell chronic
lymphocytic
leukaemia
1 0 0 1
Myeloid proliferation 1 1 3 5
• Acute myeloid
leukaemia
1 0 1 2
• Chronic
myelomonocytic
leukaemia
0 0 1 1
• Eosinophilic leukaemia 0 1 0 1
• Myelodysplastic
syndrome
0 0 1 1
Total 8 1 10 19
Bold value indicates total number of patients within this group.
Table 5 Risk of non-haematological malignancies in lymphoma-
toid papulosis (LyP) patients
Malignancy Number (%†) RR 95% CI
Cutaneous squamous
cell carcinoma
26 (6) 4.3 2.5 to 6.1
Pulmonary 21 (5) 3.7 2.1 to 5.2
Melanoma 15 (3) 4.2 1.8 to 6.6
Breast cancer 13 (3) 1.3 0.3 to 2.3
Intestinal (+rectal) 13 (3) 2.4 1.2 to 3.7
Prostate 13 (3) 1.7 0.7 to 2.7
Bladder 11 (2) 8.1 3.1 to 13.1
Kidney 4 (1) 0.8 0.8 to 2.5
Ovary 4 (1) 10 0.2 to 19.7
Stomach 4 (1) 6.9 0.1 to 13.7
Uterus 3 (1) 3.6 0.5 to 7.7
Oesophagus 2 (<1) 1.7 0.7 to 4.1
Liver 1 (<1) 2.8 2.7 to 8.4
Gall bladder 1 (<1) 3.5 3.3 to 10.2
Thyroid 1 (<1) 2.7 2.6 to 8
Cerebral 1 (<1) 2.3 2.2 to 6.8
†Percentage of LyP cohort.
CI, conﬁdence interval; RR, relative risk.
Bold value indicates statistically signiﬁcant values.
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In conclusion, the results of the present study of 504 patients
with LyP show an associated HM in 15.5% of patients and do
not support the recently reported high percentages up to 50%. It
should also be noted that the risk of a LyP patient without prior
or concurrent MF or ALCL at the time of diagnosis to develop
one of these biologically related CTCLs during follow-up is only
7% and the risk to develop extracutaneous localizations of these
conditions only 3%. The observation that LyP patients have also
an increased risk to develop cutaneous squamous cell carcinoma,
melanoma and some internal cancers has not been reported
before. Clinicians should be aware of these risks, and LyP
patients require close monitoring and regular follow-up.
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